AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 2 filers reported holding AUDENTES THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $2,262,550,000 | +1079.5% | 37,810 | +453.7% | 0.00% | – |
| Q3 2019 | $191,827,000 | +22.8% | 6,829 | +65.5% | 0.00% | – |
| Q2 2019 | $156,248,000 | -48.2% | 4,127 | -46.6% | 0.00% | -100.0% |
| Q1 2019 | $301,625,000 | +6187.8% | 7,730 | +3335.6% | 0.00% | – |
| Q4 2018 | $4,797,000 | -90.5% | 225 | -82.3% | 0.00% | – |
| Q3 2018 | $50,358,000 | +3.6% | 1,272 | 0.0% | 0.00% | – |
| Q2 2018 | $48,603,000 | -59.9% | 1,272 | -68.4% | 0.00% | – |
| Q1 2018 | $121,102,000 | +10.8% | 4,030 | +15.2% | 0.00% | – |
| Q4 2017 | $109,281,000 | +190.5% | 3,497 | +160.4% | 0.00% | – |
| Q3 2017 | $37,617,000 | +21.8% | 1,343 | -16.8% | 0.00% | – |
| Q2 2017 | $30,876,000 | +586.3% | 1,614 | +511.4% | 0.00% | – |
| Q1 2017 | $4,499,000 | +92.3% | 264 | +106.2% | 0.00% | – |
| Q4 2016 | $2,339,000 | -36.2% | 128 | -37.9% | 0.00% | – |
| Q3 2016 | $3,669,000 | – | 206 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |